Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav

Safety and Efficacy of Switching to the Travoprost/Timolol Maleate Fixed Combination (DUOTRAV®) From Prior Mono or Two-Drug Therapy in Germany

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00519753

Enrollment

522

Registered

2007-08-23

Start date

2007-08-31

Completion date

2008-12-31

Last updated

2016-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

Glaucoma

Brief summary

The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.

Interventions

DRUGTravoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)

One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Age related. * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Change in intraocular pressure at 12 weeks from travoprost prior therapy (baseline)	Baseline and 12 weeks

Secondary

Measure	Time frame
Change in intraocular pressure at 12 weeks from other prior therapies (baseline)	12 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026